Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of “Hold” by Analysts

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has been given a consensus rating of “Hold” by the fourteen analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $10.50.

A number of analysts recently issued reports on IOVA shares. Barclays raised their target price on shares of Iovance Biotherapeutics from $9.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Chardan Capital reduced their price target on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. HC Wainwright reduced their price target on Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $2.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, February 5th.

Iovance Biotherapeutics Trading Down 3.1%

NASDAQ:IOVA opened at $2.52 on Friday. Iovance Biotherapeutics has a 12-month low of $1.64 and a 12-month high of $6.09. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -2.10 and a beta of 0.76. The company’s 50-day moving average is $2.54 and its two-hundred day moving average is $2.39.

Institutional Trading of Iovance Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IOVA. Xponance LLC increased its stake in shares of Iovance Biotherapeutics by 19.4% during the 4th quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 3,950 shares during the last quarter. Raymond James Financial Inc. grew its holdings in Iovance Biotherapeutics by 1.4% in the second quarter. Raymond James Financial Inc. now owns 324,098 shares of the biotechnology company’s stock valued at $557,000 after purchasing an additional 4,618 shares during the period. R Squared Ltd grew its holdings in Iovance Biotherapeutics by 41.4% in the third quarter. R Squared Ltd now owns 16,043 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 4,700 shares during the period. Orion Investment Co increased its position in Iovance Biotherapeutics by 0.3% during the fourth quarter. Orion Investment Co now owns 1,856,934 shares of the biotechnology company’s stock worth $5,069,000 after purchasing an additional 5,150 shares during the last quarter. Finally, Flputnam Investment Management Co. raised its stake in Iovance Biotherapeutics by 35.4% during the third quarter. Flputnam Investment Management Co. now owns 20,289 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,300 shares during the period. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.